Aliyah Pabani, Howard (Jack) West and Fawzi Abu Rous
Dec 28, 2024, 18:07
Fawzi Abu Rous: The efficacy and safety of anti-angiogenesis agents in patients with squamous lung cancer
Fawzi Abu Rous, Thoracic Medical Oncologist at Henry Ford Health, shared a recent article on X:
“In this commentary, H. Jack West, Aliyah Pabani and I discuss the efficacy and safety of anti-angiogenesis agents in patients with squamous lung cancer.
With the growing experience and safety data with older agents such as Ramucirumab and newer bispecifics Ivonescimab, we believe it’s time to revise some of the outdated constraints on the use of these agents in patients with squamous non-small cell lung cancer at Lung Cancer Rx.”
Authors: Aliyah Pabani, Howard (Jack) West and Fawzi Abu Rous
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 28, 2024, 18:08
Dec 28, 2024, 18:00
Dec 28, 2024, 17:56
Dec 28, 2024, 17:37